<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Sciences pmcid: 7211516 pmid: 32383371 doi: 10.3346/jkms.2020.35.e176 : Review Article:" exact="Infectious" post="Diseases, Microbiology &amp;amp; Parasitology Perspectives of Immune Therapy in"/>
 <result pre="Diseases, Microbiology &amp;amp; Parasitology Perspectives of Immune Therapy in Coronavirus" exact="Disease" post="2019 https://orcid.org/0000-0001-8749-6018GasparyanArmen Yuri1https://orcid.org/0000-0002-5035-7396MisraDurga Prasanna2https://orcid.org/0000-0003-2511-6918YessirkepovMarlen3https://orcid.org/0000-0002-4188-8486ZimbaOlena4[1], UK[2], India[3], [4], Ukraine Address"/>
 <result pre="work is properly cited. Abstract The global fight against coronavirus" exact="disease" post="2019 (COVID-19) is largely based on strategies to boost"/>
 <result pre="largely based on strategies to boost immune responses to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe"/>
 <result pre="based on strategies to boost immune responses to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course"/>
 <result pre="on strategies to boost immune responses to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and prevent its severe course and"/>
 <result pre="actions on multiple organ systems. Protective cross-reactivity of antibodies against" exact="measles" post="and other known viral infections has been postulated, primarily"/>
 <result pre="systems. Protective cross-reactivity of antibodies against measles and other known" exact="viral" post="infections has been postulated, primarily as a result of"/>
 <result pre="Protective cross-reactivity of antibodies against measles and other known viral" exact="infections" post="has been postulated, primarily as a result of the"/>
 <result pre="of the virus structure, the utility of convalescent plasma is" exact="limited" post="to the geographic area of its preparation, and for"/>
 <result pre="to the geographic area of its preparation, and for a" exact="short" post="period of time. Intravenous immunoglobulin may also be protective"/>
 <result pre="Convalescent Serum Antibodies Immunotherapy INTRODUCTION The global fight against coronavirus" exact="disease" post="2019 (COVID-19) requires concerted efforts of all specialists with"/>
 <result pre="virus structure and its destructive actions with hyperinflammation and dreadful" exact="systemic" post="manifestations points to the necessity of a multidisciplinary approach."/>
 <result pre="be associated with aging, reduced cardiopulmonary reserves, and immune dysregulations.2" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of"/>
 <result pre="associated with aging, reduced cardiopulmonary reserves, and immune dysregulations.2 Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the"/>
 <result pre="with aging, reduced cardiopulmonary reserves, and immune dysregulations.2 Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the cause of the current"/>
 <result pre="aging, reduced cardiopulmonary reserves, and immune dysregulations.2 Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the cause of the current pandemic,"/>
 <result pre="SARS-CoV-2 has four major targets: the N protein covering the" exact="viral" post="ribonucleic acid (RNA), the E protein encompassing the viral"/>
 <result pre="the viral ribonucleic acid (RNA), the E protein encompassing the" exact="viral" post="envelope, the M protein protruding from the cell membrane"/>
 <result pre="against SARS-CoV-2. Cross-reactive antibodies which are generated in response to" exact="measles" post="and other known viral vaccines may offer a degree"/>
 <result pre="which are generated in response to measles and other known" exact="viral" post="vaccines may offer a degree of anti-SARS-CoV-2 protection (B)."/>
 <result pre="host cells (C) and dampen hyperinflammation (D). SARS-CoV-2 = severe" exact="acute" post="respiratory syndrome coronavirus 2, N = nucleocapsid, E ="/>
 <result pre="cells (C) and dampen hyperinflammation (D). SARS-CoV-2 = severe acute" exact="respiratory" post="syndrome coronavirus 2, N = nucleocapsid, E = envelope,"/>
 <result pre="(C) and dampen hyperinflammation (D). SARS-CoV-2 = severe acute respiratory" exact="syndrome" post="coronavirus 2, N = nucleocapsid, E = envelope, M"/>
 <result pre="in adults (3.5%).3 Also, with the exception of those with" exact="cardiovascular" post="and other comorbidities, children are generally less prone to"/>
 <result pre="the early stage of the pandemic are likely associated with" exact="lower" post="exposure to the virus which increased with exponential growth"/>
 <result pre="during pregnancy makes pregnant women vulnerable to COVID-19 and other" exact="viral" post="infections.9 Maternal antiviral antibody production can be suppressed until"/>
 <result pre="after delivery,10 further complicating the serodiagnostics of COVID-19. Patients with" exact="rheumatic" post="diseases, particularly those on immunosuppressive therapies, form another high-risk"/>
 <result pre="points to the risk of severe COVID-19 and death in" exact="adult" post="rheumatic patients with preexisting comorbidity (lung involvement), although the"/>
 <result pre="to the risk of severe COVID-19 and death in adult" exact="rheumatic" post="patients with preexisting comorbidity (lung involvement), although the true"/>
 <result pre="high-risk individuals with obesity, hypertension, diabetes, history of smoking and" exact="lung disease." post="The syndrome rapidly develops as an excessive immune response"/>
 <result pre="obesity, hypertension, diabetes, history of smoking and lung disease. The" exact="syndrome" post="rapidly develops as an excessive immune response to the"/>
 <result pre="physicians confronting COVID-19 are now offered practice recommendations based on" exact="uncontrolled" post="case series and expert opinion. In the absence of"/>
 <result pre="based on uncontrolled case series and expert opinion. In the" exact="absence of" post="the long-term prospective studies, hypotheses are generated to launch"/>
 <result pre="done through the prism of research reporting standards.16 In the" exact="absence of" post="highly effective antiviral drugs and approved COVID-19 vaccines, the"/>
 <result pre="A good example is a hypothesis associating mandatory vaccinations against" exact="measles" post="and other known viral diseases with cross-resistance to COVID-19"/>
 <result pre="a hypothesis associating mandatory vaccinations against measles and other known" exact="viral" post="diseases with cross-resistance to COVID-19 in children.17 The idea"/>
 <result pre="based on an observation suggesting that subjects who recover from" exact="measles" post="and those vaccinated with measles, mumps and rubella vaccine"/>
 <result pre="subjects who recover from measles and those vaccinated with measles," exact="mumps" post="and rubella vaccine produce antibodies to a variety of"/>
 <result pre="recover from measles and those vaccinated with measles, mumps and" exact="rubella" post="vaccine produce antibodies to a variety of HIV-1 proteins.18"/>
 <result pre="of the novel coronavirus in a patient with HIV and" exact="hepatitis C" post="virus co-infection and successful recovery from COVID-19 pneumonia also"/>
 <result pre="and hepatitis C virus co-infection and successful recovery from COVID-19" exact="pneumonia" post="also points to a crucial role of cross-reactive antibodies.22"/>
 <result pre="An interesting hypothesis is generated suggesting that multiple doses of" exact="tuberculosis" post="vaccine bacillus Calmette-GuÃ©rin (BCG) could be protective against COVID-19"/>
 <result pre="same strategy is proved to be safe and effective in" exact="autoimmune" post="disorders, such as type 1 diabetes mellitus and multiple"/>
 <result pre="to be safe and effective in autoimmune disorders, such as" exact="type 1 diabetes mellitus" post="and multiple sclerosis. A recent preprint revealed nonspecific beneficial"/>
 <result pre="safe and effective in autoimmune disorders, such as type 1" exact="diabetes mellitus" post="and multiple sclerosis. A recent preprint revealed nonspecific beneficial"/>
 <result pre="in autoimmune disorders, such as type 1 diabetes mellitus and" exact="multiple sclerosis." post="A recent preprint revealed nonspecific beneficial effects of universal"/>
 <result pre="number of days of unplanned absenteeism for any reason is" exact="primary" post="outcome of the trial.25 BRACE trial (BCG Vaccination to"/>
 <result pre="strategy is strongly recommended for the majority of patients with" exact="autoimmune" post="inflammatory rheumatic diseases prior to the administration of immunosuppressive"/>
 <result pre="strongly recommended for the majority of patients with autoimmune inflammatory" exact="rheumatic" post="diseases prior to the administration of immunosuppressive therapy.28 However,"/>
 <result pre="the cross-resistance to SARS-CoV-2 in individuals vaccinated against influenza or" exact="pneumococcal pneumonia." post="INTRAVENOUS IMMUNOGLOBULIN An entirely different approach is proposed by"/>
 <result pre="collected from thousands of healthy donors ameliorate the course of" exact="autoimmune" post="inflammatory rheumatic diseases by blocking Fc-gamma receptors and neutralizing"/>
 <result pre="thousands of healthy donors ameliorate the course of autoimmune inflammatory" exact="rheumatic" post="diseases by blocking Fc-gamma receptors and neutralizing inflammatory cytokines."/>
 <result pre="in convalescent serum and duration of therapy depend on the" exact="viral" post="load and severity of COVID-19. It is believed that"/>
 <result pre="administration of the serum is primarily indicated in individuals with" exact="chronic" post="underlying diseases, healthcare workers, and healthy subjects who have"/>
 <result pre="patients, antibody production increased at day 10 to 15 after" exact="disease" post="onset. Surprisingly, elderly (60â€&quot;85 years) and middle-age (40â€&quot;59) patients,"/>
 <result pre="elderly (60â€&quot;85 years) and middle-age (40â€&quot;59) patients, who presented with" exact="lower" post="lymphocyte counts and higher level inflammatory markers, produced significantly"/>
 <result pre="symptoms within 17 days of recovery, pointing to high baseline" exact="viral" post="load, various immune dysfunctions, and virus persistence.36 Interestingly, a"/>
 <result pre="173) of seroconversion and SARS-CoV-2 RNA detection rates revealed that" exact="total" post="antibodies against the virus were present in about 40%"/>
 <result pre="present in about 40% of patients within 1st week of" exact="disease" post="onset and in all patients after 2 weeks.37 During"/>
 <result pre="antibodies are able to neutralize the virus. Variable timing and" exact="deficiency" post="of antibody production in a sizable proportion of COVID-19"/>
 <result pre="high SARS-CoV-2 IgG antibodies (above 1:160) and free of any" exact="viral" post="and bacterial infections.39 An initial uncontrolled case series of"/>
 <result pre="IgG antibodies (above 1:160) and free of any viral and" exact="bacterial" post="infections.39 An initial uncontrolled case series of 5 critically-ill"/>
 <result pre="and free of any viral and bacterial infections.39 An initial" exact="uncontrolled" post="case series of 5 critically-ill Chinese patients with COVID-19"/>
 <result pre="Plasma transfusion resulted in improving the patients' clinical status, decreasing" exact="viral" post="load, and increasing titers of neutralizing antibodies within 12"/>
 <result pre="6 cases of plasma therapy in patients with COVID-19 and" exact="respiratory" post="failure at a median 21.5 days after the virus"/>
 <result pre="21.5 days after the virus detection in nasopharyngeal swabs demonstrated" exact="viral" post="clearance within 3 days in all patients.41 Eventually, only"/>
 <result pre="with severe COVID-19 treated with convalescent plasma revealed clinical and" exact="chest" post="radiology improvement in all patients. Two out of three"/>
 <result pre="this.42 Major limitation of all reported case series is the" exact="absence of" post="matched control subjects who were not on convalescent plasma"/>
 <result pre="epidemics alerted physicians of the risk of anaphylactic reactions, transfusion-related" exact="acute" post="lung injury, and hemolysis,43 no serious adverse effects have"/>
 <result pre="and explore the risk of adverse effects such as transfusion-related" exact="acute" post="lung injury. CONCLUSION The COVID-19 pandemic necessitates mobilizing all"/>
 <result pre="children, pregnant women, medics, patients with underlying immunosuppressive and other" exact="chronic" post="diseases, and the elderly. It is hypothesized that individuals"/>
 <result pre="is hypothesized that individuals regularly vaccinated against some infections, such" exact="measles" post="and tuberculosis, may demonstrate better outcomes when exposed to"/>
 <result pre="References 1collab: WorldometerCOVID-19 coronavirus pandemicUpdated 2020Accessed May 1, 2020https://www.worldometers.info/coronavirus/ 2FerdinandKCNasserSAAfrican" exact="American" post="COVID-19 mortality: a sentinel eventJ Am Coll Cardiol 3SheJLiuLLiuWCOVID-19"/>
 <result pre="COVID-19 mortality: a sentinel eventJ Am Coll Cardiol 3SheJLiuLLiuWCOVID-19 epidemic:" exact="disease" post="characteristics in childrenJ Med Virol 4AhmedSFQuadeerAAMcKayMRPreliminary identification of potential"/>
 <result pre="the paediatric rheumatologistClin Immunol202021410842032283324 8TagarroAEpalzaCSantosMSanz-SantaeufemiaFJOtheoEMoraledaCet al.Screening and severity of coronavirus" exact="disease" post="2019 (COVID-19) in children in Madrid, SpainJAMA PediatrForthcoming 2020"/>
 <result pre="(COVID-19) in children in Madrid, SpainJAMA PediatrForthcoming 2020 9DashraathPWongJLLimMXLimLMLiSBiswasAet al.Coronavirus" exact="disease" post="2019 (COVID-19) pandemic and pregnancyAm J Obstet GynecolForthcoming 2020"/>
 <result pre="possible vertical transmissionAm J PerinatolForthcoming 2020 11MisraDPAgarwalVGasparyanAYZimbaORheumatologists' perspective on coronavirus" exact="disease" post="19 (COVID-19) and potential therapeutic targetsClin RheumatolForthcoming 2020 12FavalliEGAgapeECaporaliRIncidence"/>
 <result pre="13FavalliEGIngegnoliFCimazRCaporaliRWhat is the true incidence of COVID-19 in patients with" exact="rheumatic" post="diseases?Ann Rheum DisForthcoming 2020 14YeQWangBMaoJThe pathogenesis and treatment of"/>
 <result pre="high cardiorespiratory fitness confer some protection against pro-inflammatory responses after" exact="infection" post="by SARS-CoV-2?Obesity (Silver Spring)Forthcoming 2020 16GasparyanAYAyvazyanLMukanovaUYessirkepovMKitasGDScientific hypotheses: writing, promoting,"/>
 <result pre="hypotheses: writing, promoting, and predicting implicationsJ Korean Med Sci20193445e30031760713 17SalmanSSalemMLRoutine" exact="childhood" post="immunization may protect against COVID-19Med Hypotheses202014010968932240961 18BaskarPVCollinsGDDorsey-CooperBAPyleRSNagelJEDwyerDet al.Serum antibodies"/>
 <result pre="28FurerVRondaanCHeijstekMWAgmon-LevinNvan AssenSBijlMet al.2019 update of EULAR recommendations for vaccination in" exact="adult" post="patients with autoimmune inflammatory rheumatic diseasesAnn Rheum Dis2020791395231413005 29JawharaSCould"/>
 <result pre="update of EULAR recommendations for vaccination in adult patients with" exact="autoimmune" post="inflammatory rheumatic diseasesAnn Rheum Dis2020791395231413005 29JawharaSCould Intravenous immunoglobulin collected"/>
 <result pre="EULAR recommendations for vaccination in adult patients with autoimmune inflammatory" exact="rheumatic" post="diseasesAnn Rheum Dis2020791395231413005 29JawharaSCould Intravenous immunoglobulin collected from recovered"/>
 <result pre="immunoglobulin as a therapeutic option for deteriorating patients with coronavirus" exact="disease" post="2019Open Forum Infect Dis202073a102 32FauciASLaneHCRedfieldRRCOVID-19 - navigating the unchartedN"/>
 <result pre="implicationsUpdated 2020Accessed May 1, 2020https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2.full.pdf10.1101/2020.03.30.20047365 36YeGPanZPanYDengQChenLLiJet al.Clinical characteristics of severe" exact="acute" post="respiratory syndrome coronavirus 2 reactivationJ Infect2020805e14e1732171867 37ZhaoJYuanQWangHLiuWLiaoXSuYet al.Antibody responses"/>
 <result pre="2020Accessed May 1, 2020https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2.full.pdf10.1101/2020.03.30.20047365 36YeGPanZPanYDengQChenLLiJet al.Clinical characteristics of severe acute" exact="respiratory" post="syndrome coronavirus 2 reactivationJ Infect2020805e14e1732171867 37ZhaoJYuanQWangHLiuWLiaoXSuYet al.Antibody responses to"/>
 <result pre="May 1, 2020https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2.full.pdf10.1101/2020.03.30.20047365 36YeGPanZPanYDengQChenLLiJet al.Clinical characteristics of severe acute respiratory" exact="syndrome" post="coronavirus 2 reactivationJ Infect2020805e14e1732171867 37ZhaoJYuanQWangHLiuWLiaoXSuYet al.Antibody responses to SARS-CoV-2"/>
 <result pre="37ZhaoJYuanQWangHLiuWLiaoXSuYet al.Antibody responses to SARS-CoV-2 in patients of novel coronavirus" exact="disease" post="2019Clin Infect Dis 38MallapatySWill antibody tests for the coronavirus"/>
 <result pre="with convalescent plasmaJAMA2020323161582 41ZengQLYuZJGouJJLiGMMaSHZhangGFet al.Effect of convalescent plasma therapy on" exact="viral" post="shedding and survival in COVID-19 patientsJ Infect Dis 42DuanKLiuBLiCZhangHYuTQuJet"/>
</results>
